Dorien De Pooter

Ms. Dorien De Pooter

Janssen (Belgium), Beerse, Belgium
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
DPDorien De Pooter
Dorien De Pooter
EGEllen Van Gulck
Ellen Van Gulck
ACAntony Chen
Antony Chen
CEClaire F. Evans
Claire F. Evans
JNJean-Marc Neefs
Jean-Marc Neefs
DBDaniel Boden
Daniel Boden
Despite the availability of an effective prophylactic vaccine for more than 30 years, nearly 300 million people worldwide are chronically infected with the hepatitis B virus (HBV), leading to 1 death every 30 s mainly from viral hepatitis-related cirrhosis and liver cancer. Chronic HBV patients exhibit weak, transient, or dysfunctional CD8+ T-cell responses to HBV, which contrasts with high CD8+ T-cell responses seen for resolvers of acute HBV infection. Therefore, a therapeutic DNA vaccine was designed, expressing both HBV core and polymerase proteins, and was sequence optimized to ensure high protein expression and secretion. Although the vaccine, administered intramuscularly via electroporation, had no effect on plasma viral parameters in a mouse model of persistent HBV infection, it did induce robust HBV-specific immune responses in healthy and adeno-associated hepatitis B virus (AAV-HBV) infected mice as well as in healthy non-human primates.

25 February 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
DPDorien De Pooter
Dorien De Pooter
WPWim Pierson
Wim Pierson
SPSoheil Pourshahian
Soheil Pourshahian
KDKoen Dockx
Koen Dockx
BCBen De Clerck
Ben De Clerck
DBDaniel Boden
Daniel Boden
Chronic infection with hepatitis B virus (HBV) develops in millions of patients per year, despite the availability of effective prophylactic vaccines. Patients who resolve acute HBV infection develop HBV-specific polyfunctional T cells accompanied by neutralizing antibodies, while in patients with chronic hepatitis B (CHB), immune cells are dysfunctional and impaired. We describe a lipid nanoparticle (LNP)-formulated mRNA vaccine, optimized for the expression of HBV core, polymerase, and surface (preS2-S) antigens with the aim of inducing an effective immune response in patients with CHB. Prime and prime/boost vaccination with LNP-formulated mRNA encoding for core, pol, and/or preS2-S dosing strategies were compared in naive C57BL/6 and BALB/c mice. Immune responses were assessed by IFN-γ ELISpot, intracellular cytokine staining (ICS), and ELISA for antibody production, whereas anti-viral efficacy was evaluated in the AAV-HBV mouse model. The mRNA vaccine induced strong antigen-specific polyfunctional T cell responses in these mouse models, accompanied by the emergence of anti-HBs and anti-HBe antibodies. After three immunizations, the antigen-specific immune stimulation resulted in up to 1.7 log10 IU/mL reduction in systemic HBV surface antigen (HBsAg), accompanied by a transient drop in systemic HBeAg, and this was observed in 50% of the AAV-HBV-transduced mice in the absence of additional modalities such as adjuvants, HBsAg reducing agents, or checkpoint inhibitors. However, no treatment-related effect on viremia was observed in the liver. These results warrant further optimization and evaluation of this mRNA vaccine as a candidate in a multimodal therapeutic regimen for the treatment of chronic HBV infection.

6 December 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
NCNádia Conceição-Neto
Nádia Conceição-Neto
WPWim Pierson
Wim Pierson
MVMaurizio Vacca
Maurizio Vacca
MBMatthias Beyens
Matthias Beyens
BCBen De Clerck
Ben De Clerck
EGEllen Van Gulck
Ellen Van Gulck
Background: Suppression of HBV DNA, inhibition of HBV surface (HBsAg) production and therapeutic vaccination to reverse HBV-specific T-cell exhaustion in chronic HBV patients are likely required to achieve a functional cure. In the AAV-HBV mouse model, therapeutic vaccination can be effective in clearing HBV when HBsAg levels are low. Using a single-cell approach, we investigated the liver immune environment with different levels of HBsAg and sustained HBsAg loss through treatment with a GalNAc-HBV-siRNA followed by therapeutic vaccination. Methods: AAV-HBV-transduced C57BL/6 mice were treated with GalNAc-HBV-siRNA to lower HBsAg levels and then vaccinated using a DNA vaccine. We used single-cell RNA and V(D)J sequencing to understand liver immune microenvironment changes. Results: GalNAc-HBV-siRNA, followed by therapeutic vaccination, achieved sustained HBsAg loss in all mice. This was accompanied by CD4 follicular helper T-cell induction, polyclonal activation of CD8 T cells and clonal expansion of plasma cells that were responsible for antibody production. Conclusions: This study provides novel insights into liver immune changes at the single-cell level, highlighting the correlation between induced reduction of HBsAg levels and clonal expansion of CD4, CD8 T cells and plasma cells in the liver upon HBV siRNA and subsequent therapeutic vaccination.

3 July 2024
Verified
Thesis
Closed access
DPDorien De Pooter
Dorien De Pooter
Yearly, 1.5 million people get infected with the hepatitis B virus, although preventive vaccines are available. People who are not able to take control of the virus, especially infants, develop a chronic infection. As HBV targets the hepatocytes, a chronic infection can permanently damage the liver and can lead to the development of hepatocellular carcinoma. The hepatitis B virus is able to form circular covalently closed (ccc)DNA in infected hepatocytes and to integrate its DNA in the genome of the host. Both integrated DNA and cccDNA are a source for persistent high concentrations of viral antigens like HBsAg, and cause an immune system tolerant to it, with exhausted T-cells unable to kill infected hepatocytes. Current therapies can not eliminate the virus completely and there is need for a therapy that can reach functional cure, defined as the loss of systemic HBsAg levels and undetectable levels of HBV DNA after a finite treatment. It is believed that a successful treatment consists of multiple modalities including antivirals and immunomodulators that target the high viral and antigen burden as well as inadequate host immune responses. One such immunomodulator is a therapeutic vaccine that introduces HBV viral antigens to the body thereby eliciting a specific immune response. This thesis describes the development and preclinical evaluation of a pDNA vaccine encoding core and pol HBV antigen and a second vaccine in the form of mRNA encoding core, pol and envelope antigen. Robust immune responses were induced in several naive animals with the mRNA vaccine being superior in terms of magnitude of induced CD8 T-cell responses, but specifically the core-specific CD4 T-cell responses were negatively impacted compared to the pDNA vaccine. In AAV-HBV transduced mice, containing an HBV-tolerant, immune suppressed liver environment, the elicited immune responses after two immunizations with pDNA vaccine, were not powerful enough to reduce viral parameters while responses after three immunizations with the mRNA vaccine, reduced viral parameters for 50% of the tested mice. The used platforms allow multiple improvement such as coadministration with adjuvants, altering dosing scheme, finetuning the formulation, exploration of a heterologous regimens, ... The combination of a vaccine with modalities to reduce viral replication and reduce the suppressive HBV antigen levels, should strengthen, and enhance it effects. Such a multimodal therapy is believed to be essential to reduce changes of developing liver damage caused by the constant presence of hepatitis B virus.